ADVFN US – Market Content Editor
-
Gold Steadies as Market Awaits US Employment Figures for Fed Guidance
Gold prices held firm during Thursday’s Asian session, maintaining gains accumulated over the past three days as investors adopt a cautious stance ahead of the highly anticipated U.S. non-farm payroll report, a key indicator for the Federal Reserve’s next policy decisions. The precious metal found support amid ongoing worries about the growing U.S. fiscal deficit,…
-
Oil Prices Ease as U.S. Inventory Gains Raise Demand Concerns Ahead of OPEC+ Meeting
Oil prices pulled back during Asian trading on Thursday, giving up some of the strong gains recorded in the previous session after U.S. government data showed a larger-than-expected increase in crude stockpiles. This unexpected build heightened worries about weakening fuel demand amid a backdrop of rising supply. Oil prices had jumped between 2.5% and 3%…
-
U.S. Removes Export Restrictions on Chip Design Technology to China; Shares of Cadence and Synopsys Surge
The U.S. Department of Commerce has lifted the export restrictions on chip design technology destined for China, according to company disclosures released Wednesday evening. This development is part of ongoing trade negotiations between Washington and Beijing. Following the announcement, shares of leading chip design firms Synopsys Inc (NASDAQ:SNPS) and Cadence Design Systems Inc (NASDAQ:CDNS) saw…
-
Nasdaq, S&P 500 Rebound To Record Closing Highs After Vietnam Trade Deal
Stocks moved mostly higher over the course of the trading session on Wednesday, with the Nasdaq and the S&P 500 moving back to the upside following the pullback seen during Tuesday’s trading. The Nasdaq and the S&P 500 more than offset yesterday’s losses, once again reaching new record closing highs. The tech-heavy Nasdaq jumped 190.24…
-
Regeneron Shares Climb Following FDA Approval of Blood Cancer Treatment
Regeneron Pharmaceuticals (NASDAQ:REGN) saw its stock increase by 2.8% after the U.S. Food and Drug Administration granted accelerated approval for its new blood cancer drug, Lynozyfic. Lynozyfic (linvoseltamab-gcpt) is now approved to treat adults with relapsed or refractory multiple myeloma who have undergone at least four previous treatment regimens. The FDA’s decision was supported by…
-
KLA Corporation Stock Hits New Record at $915.10
KLA Corporation’s (NASDAQ:KLAC) stock soared to a new all-time high of $915.10, reaching a market capitalization of approximately $120 billion. The semiconductor equipment giant has delivered stellar gains, rising more than 40% over the last six months, fueled by robust demand in the technology sector. The company’s revenue growth remains strong at 20% year-over-year, supported…
-
Jabil Circuit Hits Record High on AI-Driven Growth Outlook
Jabil Circuit (NYSE:JBL) stock surged to a fresh all-time high of $219.14, fueled by investor optimism surrounding the company’s accelerating growth in artificial intelligence and cloud infrastructure. With this rally, Jabil’s market valuation has climbed to $23.45 billion, reflecting a near 100% return over the past year. The surge in share price is backed by…
-
Dianthus Therapeutics Shares Climb After Analyst Coverage Boost
Shares of Dianthus Therapeutics (NASDAQ:DNTH) jumped 5.8% after William Blair initiated coverage on the stock with an Outperform rating, marking the 13th buy recommendation the clinical-stage biotech has received. Analyst Mylers Minter led the coverage, assigning a fair value of $47.57 per share, highlighting the company’s potential in the autoimmune space. Dianthus is currently developing…
-
Seagate Technology Hits Record High as Analyst Optimism Grows
Seagate Technology PLC (NASDAQ:STX) shares reached a new all-time high of $147.75, pushing the company’s market capitalization beyond $31 billion. The milestone caps a strong 12-month run for the data storage leader, with the stock up 45.6% year-over-year, reflecting growing investor confidence in Seagate’s positioning in a rapidly evolving tech landscape. The company’s robust fundamentals…
-
Oscar Health slides after Barclays initiates coverage with bearish outlook
Oscar Health (NYSE:OSCR) shares fell sharply on Wednesday, dropping 14% to $17.58, after Barclays initiated coverage with an Underweight rating, cautioning that the stock’s recent surge leaves it exposed to downside risks. The insurer saw its shares rise over 50% in June, largely fueled by retail enthusiasm following a bullish investor day presentation. However, Barclays…